27 agosto 2015
Use of the 21-gene recurrence test score was associated with lower chemotherapy use in high-risk patients and greater use of chemotherapy in low-risk patients compared with not using the test among a large group of Medicare beneficiaries, according to a new article.
http://www.sciencedaily.com/releases/2015/08/150827121912.htm
